INSILICO: Discovering the Fountain of Youth - You're Not Getting Any Older !!
Insilico Medicine (3696 HK) has risen since its 1H26 earnings announcement. The company's rentosertib drug reversed biological aging markers in...
97 Views
InSilico Medicine (3696 HK): Pipeline Is Progressing; 1H Sales Jump 4x on BD Deals; Turns Profitable
InSilico's lead asset rentosertib has demonstrated potential for biological age reversal. In 1H26, revenue increased 287% to $106M, and the company...
84 Views
InSilico Medicine 3696.HK - 1H26 Results Call Takeaways: BD Deals, AI “Gym” Execution, PCC Momentum
2026E revenue guidance (USD150-200m) remains intact. We believe the stock narrative hinges on: 1) BD deal flows, 2) pipeline: PCC momentum +...
105 Views
APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
HONG KONG ALPHA PORTFOLIO: (September 2026)
HK Alpha portfolio gained 2.22% in September, outperforming its benchmark by 5.36%. Since inception, the portfolio has outperformed HK indexes by...
99 Views